Targets, Tracers and Translation – Novel Radiopharmaceuticals Boost Nuclear Medicine

Guest Editor:

PD Dr. Gerald Reischl
Universität Tubingen,
Department of Preclinical Imaging and Radiopharmacy,
Tubingen, Germany
gerald.reischl@med.uni-tuebingen.de

Deadline for manuscript submissions:
closed (14 January 2019)

Message from the Guest Editor

This is the 4th Special Issue in *Pharmaceuticals* within the last five years dealing with aspects of Radiopharmaceutical Sciences. It demonstrates a significant interest and increasing relevance to ameliorate Nuclear Medicine imaging with PET or SPECT, and also radiotherapeutical procedures. Numerous targets and mechanisms have been identified and have been under investigation over the previous years, covering many fields of medical and clinical research. In addition to the classical PET isotopes (¹⁸F, ¹¹C, ¹³N, ¹⁵O) further nuclides are available (e.g., ⁶⁸Ga, ⁶⁴Cu, ⁸⁹Zr, ⁴⁴Sc). There are also new labeling techniques under development to aim for new highly specific tracers (radiopharmaceuticals) to investigate the targets. Large variety of accessible animal and cell models for the preclinical evaluation of targets, mechanisms and tracers have to be highlighted. You are cordially invited to contribute original research, as well as review articles, to this Special Issue. Areas of interest include but are not limited to:

- New targets for imaging
- Tracer developments towards translation
- Multi-modal imaging
- Studies of tumor pathways
- Imaging for therapy monitoring
Editor-in-Chief

Dr. Jean Jacques Vanden Eynde
Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal Pharmaceuticals.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to Pharmaceuticals soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: citations available in PubMed, full-text archived in PubMed Central. Covered by Embase and Scopus. To be indexed in the Emerging Sources Citation Index - ESCI (Web of Science) from Vol. 10 (2017).

CiteScore: 4.20, based on citations in 2017 to articles published 2014-2016.

Contact Us

Pharmaceuticals
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com

pharmaceuticals@mdpi.com

pharmaceuticals@mdpi.com